Log in to search using one of your social media accounts:

 

FDA Considers Gene Therapy for Rare Eye Disease

If approved, it would be only the 2nd gene therapy OK'd in the United States
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

Condition:   Hemophilia B Intervention:   Biological: FLT180a Sponsor:   University College, London Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
PARIS, December 12, 2017 -- (Healthcare Sales &Marketing Network) -- Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced the appointment of Dr. Patricia Zilliox as CEO. Dr. Zilliox, ... Biopharmaceuticals, Ophthalmology, Personnel Eyevensys, EyeCET, gene therapy, electro-transfection injection
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer, Published online: 12 December 2017; doi:10.1038/s41417-017-0003-0LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
by Sudhir Kumar Rai, Maya Sangesland, Michael Lee Jr., Caroline Esnault, Yujin Cui, Atreyi Ghatak Chatterjee, Henry L. Levin Retroviruses and Long Terminal Repeat (LTR)-retrotransposons have distinct patterns of integration sites. The oncogenic potential of retrovirus-based vectors used in gene therapy is dependent on the selection of integration sites associated with promoters. The LTR-retrotransposon Tf1 ofSchizosaccharomyces pombe is studied as a model for oncogenic retroviruses because it integrates into the promoters of stress response genes. Although integrases (INs) encoded by retroviruses and LTR-retrotransposons ...
Source: PLoS Genetics - Category: Genetics & Stem Cells Authors: Source Type: research
Spark Therapeutics ’ stock price plunged more than 40 percent Monday morning after the Philadelphia-based gene therapy company provided an update of its experimental hemophilia A treatment. Preliminary clinical data showed the gene therapy treatments produced significant reductions in bleeding rates, but yielded mu ch lower increases in levels of factor VIII — the clotting protein missing in hemophilia A patients. California-based BioMarin Pharmaceutical released study results on Saturday of…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Spark Therapeutics, the company likely to launch the first gene therapy in the U.S., is presenting data on both of its gene therapies for hemophilia this morning at the annual meeting of the American Society of Hematology in Atlanta.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:ONCE NASDAQ:BMRN Source Type: news
Title: New Gene Therapy May Be Cure for 'Bubble Boy' DiseaseCategory: Health NewsCreated: 12/9/2017 12:00:00 AMLast Editorial Review: 12/11/2017 12:00:00 AM
Source: MedicineNet Kids Health General - Category: Pediatrics Source Type: news
This article is protected by copyright. All rights reserved.
Source: Acta Physiologica - Category: Physiology Authors: Tags: Review Article Source Type: research
Human Gene Therapy , Vol. 0, No. 0.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy , Vol. 0, No. 0.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
More News: Gene Therapy | Genetics | Health | USA Health